RESUMO
Scientific journals have changed the mechanisms they use for distribution and dissemination of information. Different approaches towards determining impact have emerged and among these, metrics derived from activity on social media are an emerging trend. This article aims to assess whether a correlation exists between the traditional impact factor and activity on social media. We assessed journals categorized within the area of "immunology" on the SCImago Journal and Country Rank website. Variables reflecting traditional and alternative measures of impact were collected. Differences between journals with and without social networks were assessed using non-parametric Mann-Whitney U tests. Correlation was assessed through Spearman tests. 156 journals were analyzed, 17% had at least one social network. 48.2% of journals with social networks were classified within SJR's quartile 1. An almost perfect correlation was found between the SJR and the number of followers on Twitter, this correlation remained statistically significant after adjusting for time since creation of the account [Spearman's correlation (rs) = 0.83]. We propose the use of Twitter as a mechanism for dissemination of information by immunology journals, as well as other social networks for their potential to increase their audience, as well as the dissemination and impact of their publications.
Assuntos
Alergia e Imunologia , Disseminação de Informação , Fator de Impacto de Revistas , Publicações Periódicas como Assunto , Mídias Sociais , Humanos , Redes Sociais OnlineRESUMO
Case description: A 61-year-old male patient with uncontrolled rheumatoid arthritis presented acute coronary syndrome on three occasions, less than 48 hours after infliximab infusion. Clinical findings: He presented with ST-elevation myocardial infarction on two occasions and non-ST-elevation acute coronary syndrome on one, with the identification of multivessel coronary disease. Treatment and outcome: Coronary intervention was performed with thrombus aspiration, medicated stent implantation, medicated balloon angioplasty, discontinuation of infliximab, and modification and optimization of cardiovascular pharmacological management. Clinical relevance: Patients with rheumatoid arthritis have subclinical cardiovascular disease and increased cardiovascular risk. The evidence regarding the relationship between infliximab and ischemic heart disease is controversial. A wide clinical spectrum of cardiac involvement with infliximab infusion is found in case reports, ranging from stable angina to ST-segment elevation acute coronary syndrome. The pathophysiology is not elucidated, with hypotheses proposing plaque rupture, allergic reactions, and vasoconstriction as possible disease mechanisms. The direct association between infliximab infusion and acute coronary syndrome needs more clinical research to optimize the management and prognosis of patients presenting with this type of complication.
Descripción del caso: Paciente masculino de 61 años con artritis reumatoide no controlada, en manejo con infliximab, quién presentó en tres oportunidades síndrome coronario agudo menos de 48 horas posterior a la aplicación del medicamento. Hallazgos clínicos: Presentó infarto con elevación del ST en dos ocasiones y síndrome coronario agudo sin elevación del ST en una oportunidad, encontrándose enfermedad coronaria multivaso. Tratamiento y resultado: Se realizó intervención coronaria con tromboaspiración, implante de stents medicados y angioplastia con balón medicado, suspensión del infliximab y modificación y optimización de manejo farmacológico cardiovascular. Relevancia clínica: Los pacientes con artritis reumatoide tienen enfermedad cardiovascular subclínica y mayor riesgo cardiovascular. La evidencia respecto a la relación entre infliximab y cardiopatía isquémica es controversial. En reportes de caso se encuentra un amplio espectro clínico de compromiso cardíaco con la infusión de infliximab, que va desde la angina estable hasta el síndrome coronario agudo con elevación del segmento ST. La fisiopatología no está claramente dilucidada, con hipótesis que proponen la ruptura de placa, reacciones alérgicas y la vasoconstricción como posibles mecanismos de enfermedad. La asociación directa entre la infusión de infliximab y el síndrome coronario agudo necesita más investigación clínica con el fin de optimizar el manejo y pronóstico de los pacientes que presentan este tipo de complicaciones.
Assuntos
Síndrome Coronariana Aguda , Artrite Reumatoide , Masculino , Humanos , Pessoa de Meia-Idade , Infliximab/efeitos adversos , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológicoRESUMO
Considerable variability exists in the way health-care providers treat patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Latin America. The most frequently used treatments for ANCA-associated vasculitis are cyclophosphamide and prolonged glucocorticoid tapers; however, randomised controlled trials conducted over the past 30 years have led to the development of several evidence-based treatment alternatives for these patients. Latin America faces socioeconomic challenges that affect access to care, and the use of certain costly medications with proven efficacy ANCA-associated vasculitis is often restricted. For these reasons, the Pan American League of Associations for Rheumatology developed the first ANCA-associated vasculitis treatment guidelines tailored for Latin America. A panel of local vasculitis experts generated clinically meaningful questions related to the treatment of ANCA-associated vasculitis using the Population, Intervention, Comparator, and Outcome (PICO) format. Following the Grading of Recommendations Assessment, Development, and Evaluation methodology, a team of methodologists conducted a systematic literature review. The panel of vasculitis experts voted on each PICO question and made recommendations, which required at least 70% agreement among the voting members. 21 recommendations and two expert opinion statements for the treatment of ANCA-associated vasculitis were developed, considering the current evidence and the socioeconomic characteristics of the region. These recommendations include guidance for the use of glucocorticoids, non-glucocorticoid immunosuppressants, and plasma exchange.
Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos , Reumatologia , Humanos , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico , Anticorpos Anticitoplasma de Neutrófilos , Glucocorticoides/uso terapêutico , Troca Plasmática , PlasmafereseRESUMO
INTRODUCTION: Studies conducted by various scientific societies have shown that the demand for specialized rheumatology care is greater than the projected growth of the workforce. Our research aims to assess the current status of the rheumatology workforce in Latin America. METHOD: This is a descriptive, cross-sectional study. A survey was created on the RedCap platform. Data were analyzed with STATA 15® Software. We present descriptive analyses. The rate of inhabitants per rheumatologist was calculated using the number of rheumatologists practicing in each country and the inhabitants for year 2020. RESULTS: Our sample was composed by 19 PANLAR member countries in Latin America. Latin America has one rheumatologist per 106,838 inhabitants. The highest rate of rheumatologist per inhabitants was found in Uruguay (1 per 27,426 inhabitants), and the lowest was found in Nicaragua (1 per 640,648 inhabitants). Mean age was 51.59 (SD12.70), ranging between 28 and 96 years of age. Mean monthly compensation was USD $2382.6 (SD$1462.5). The country with lowest salary was Venezuela ($197), whereas the highest was Costa Rica ($4500). CONCLUSIONS: There is a high variability in rheumatologists' workforce characteristics in Latin America. These results could lead to policies aiming to increase the availability and income of rheumatologists, in order to increase opportunity and quality of care of patients living with rheumatic diseases. Key Points ⢠The rheumatologists' workforce varies significantly among Latin American countries. ⢠The supply of rheumatologists is insufficient for meeting the increasing need for specialists in this field.
Assuntos
Reumatologistas , Reumatologia , Estudos Transversais , Humanos , América Latina , Pessoa de Meia-Idade , Venezuela , Recursos HumanosRESUMO
AIMS: Traditional journal level metrics, as the impact factor or Scimago journal ranking indicator (SJR) measure the impact of research on other researchers, but fail to assess the reach of these publications among wider audiences. This study aims to assess the correlation between SJR and metrics of presence on social networks of endocrinology journals. MATERIALS AND METHODS: Journals within the area of endocrinology, diabetes and metabolism were identified from the electronic portal Scimago Journal and Country Rank, and their metrics based on the number of citation collected. Different metrics of the presence on social networks, such as the number of followers and number of tweets, were assessed. The correlation between both metrics was evaluated by calculating the Spearman correlation coefficient. RESULTS: Of the 232 journals evaluated, 28 (12.1%) had social networks. The median SJR (1.53 vs 0.60, pâ¯<â¯0.01), and H index (58.5 vs 22, pâ¯<â¯0.01) were significantly higher among journals with social networks. The correlation between the number of followers on twitter and the SJR was moderate (râ¯=â¯0.60, pâ¯<â¯0.05), and it was better in journals with more than 500 publications in the last 3 years (râ¯=â¯0.85, pâ¯<â¯0.05). The number of tweets also had a moderate correlation with the SJR (râ¯=â¯0.59, pâ¯<â¯0.05) CONCLUSIONS: Our results suggest that the dissemination of research on social networks is moderately related to the traditional metrics of impact. Both types of metrics offer complementary information: while metrics based on social media may not perfectly predict the impact a scientific journal, it does have the advantage of immediacy.
Assuntos
Pesquisa Biomédica/normas , Fator de Impacto de Revistas , Publicações Periódicas como Assunto/estatística & dados numéricos , Mídias Sociais/normas , Rede Social , Benchmarking , Bibliometria , Humanos , Disseminação de Informação , Publicações Periódicas como Assunto/normasRESUMO
INTRODUCTION: The Scimago Journal Rank (SJR) impact factor is extensively used. However, as the Internet has become widely available, new metrics are coming into play. Our research aims to determine whether a correlation between the SJR impact factor and metrics reflecting social media activity does exist. MATERIALS AND METHODS: We have used pulmonary medicine journals indexed in the SJR. Variables of social network usage have been extracted from verified accounts. Bivariate analyses have been performed with the Mann-Whitney U tests, the correlation between social media-derived variables and the SJR impact factor have been assessed with the Spearman correlation coefficient. Results are presented before and after adjustment for the years since the creation of the accounts. RESULTS: From 130 journals, 38 had at least one social network account, Twitter being the most commonly used (22.85%). The H index was higher in journals with social network accounts (Median 60 vs 17; p < 0.01). The global correlation between the SJR and the number of followers on Twitter revealed moderate agreement (r = 0.46; p < 0.01), which was excellent in open access journals (rs = 0.90; p < 0.05). CONCLUSIONS: The use of social networks is directly correlated with traditional indicators of scientific impact. The joint use of alternative and traditional metrics may be useful for journals in order to generate strategies aiming to increase their audience, as well as for researchers when deciding about the best option of disseminating their articles.
Assuntos
Benchmarking/estatística & dados numéricos , Publicações Periódicas como Assunto/estatística & dados numéricos , Pneumologia , Mídias Sociais/estatística & dados numéricos , Rede Social , Sociedades Médicas/estatística & dados numéricos , Bases de Dados Bibliográficas/estatística & dados numéricos , Humanos , Internet , Fator de Impacto de RevistasRESUMO
Case description: A 61-year-old male patient with uncontrolled rheumatoid arthritis presented acute coronary syndrome on three occasions, less than 48 hours after infliximab infusion. Clinical findings: He presented with ST-elevation myocardial infarction on two occasions and non-ST-elevation acute coronary syndrome on one, with the identification of multivessel coronary disease. Treatment and outcome: Coronary intervention was performed with thrombus aspiration, medicated stent implantation, medicated balloon angioplasty, discontinuation of infliximab, and modification and optimization of cardiovascular pharmacological management. Clinical relevance: Patients with rheumatoid arthritis have subclinical cardiovascular disease and increased cardiovascular risk. The evidence regarding the relationship between infliximab and ischemic heart disease is controversial. A wide clinical spectrum of cardiac involvement with infliximab infusion is found in case reports, ranging from stable angina to ST-segment elevation acute coronary syndrome. The pathophysiology is not elucidated, with hypotheses proposing plaque rupture, allergic reactions, and vasoconstriction as possible disease mechanisms. The direct association between infliximab infusion and acute coronary syndrome needs more clinical research to optimize the management and prognosis of patients presenting with this type of complication.
Descripción del caso: Paciente masculino de 61 años con artritis reumatoide no controlada, en manejo con infliximab, quién presentó en tres oportunidades síndrome coronario agudo menos de 48 horas posterior a la aplicación del medicamento. Hallazgos clínicos: Presentó infarto con elevación del ST en dos ocasiones y síndrome coronario agudo sin elevación del ST en una oportunidad, encontrándose enfermedad coronaria multivaso. Tratamiento y resultado: Se realizó intervención coronaria con tromboaspiración, implante de stents medicados y angioplastia con balón medicado, suspensión del infliximab y modificación y optimización de manejo farmacológico cardiovascular. Relevancia clínica: Los pacientes con artritis reumatoide tienen enfermedad cardiovascular subclínica y mayor riesgo cardiovascular. La evidencia respecto a la relación entre infliximab y cardiopatía isquémica es controversial. En reportes de caso se encuentra un amplio espectro clínico de compromiso cardíaco con la infusión de infliximab, que va desde la angina estable hasta el síndrome coronario agudo con elevación del segmento ST. La fisiopatología no está claramente dilucidada, con hipótesis que proponen la ruptura de placa, reacciones alérgicas y la vasoconstricción como posibles mecanismos de enfermedad. La asociación directa entre la infusión de infliximab y el síndrome coronario agudo necesita más investigación clínica con el fin de optimizar el manejo y pronóstico de los pacientes que presentan este tipo de complicaciones.
RESUMO
RESUMEN INTRODUCCIÓN: Las enfermedades neurológicas constituyen gran parte de las urgencias médicas (10 %-15%). Por ende, se hace necesario el reconocimiento de la distribución de las principales condiciones tanto en urgencias como en hospitalización. Se decidió caracterizar la distribución real de la enfermedad neurológica atendida en un hospital universitario de tercer nivel en Boyacá. MATERIALES Y MÉTODOS: Estudio descriptivo de corte transversal. RESULTADOS: 1203 pacientes con edad promedio de 56,2 (± 21,2) años, la mayoría de sexo masculino, casi la mitad de ellos nivel de educación básica primaria. De un total de 81 diagnósticos, se caracterizaron clínica y sociodemográficamente los 12 primeros, encontrando que en el área de urgencias prevalece la enfermedad cerebrovascular, epilepsia, cefalea, polineuropatia y vértigo. CONCLUSIONES. Los principales motivos de interconsulta del servicio son la enfermedad cerebrovascular y el delirio en urgencias e internación respectivamente, siendo generadas principalmente por medicina general, medicina interna y unidad de cuidado intensivo.
ABSTRACT INTRODUCTION: Neurological diseases constitute a large proportion of medical emergencies (10%-15%). Knowledge of the distribution of the main neurological conditions both in the emergency room and in hospitalization is necessary. The real distribution of neurological disease treated in a tertiary university hospital in Boyacá can be characterized. METHODOLOGY: Descriptive cross-sectional study. Results: 1203 patients with a mean age of 56.2 (± 21.2) years, most of them male, almost half of them with basic primary education. From a total of 81 diagnoses, the first 12 were characterized clinically and socio demographically, we found that in the emergency department, cerebrovascular disease, epilepsy, headache, polyneuropathy and vertigo prevailed. CONCLUSIONS. The main reasons for consultation were cerebrovascular disease and delirium in the emergency department and hospitalization, respectively, being mainly generated by internal medicine and the intensive care unit.
Assuntos
Epidemiologia , Doenças do Sistema Nervoso , NeurologiaRESUMO
In Colombia, diabetes mellitus is a public health program for those responsible for creating and implementing strategies for prevention, diagnosis, treatment, and follow-up that are applicable at all care levels, with the objective of establishing early and sustained control of diabetes. A clinical practice guide has been developed following the broad outline of the methodological guide from the Ministry of Health and Social Welfare, with the aim of systematically gathering scientific evidence and formulating recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. The current document presents in summary form the results of this process, including the recommendations and the considerations taken into account in formulating them. In general terms, what is proposed here is a screening process using the Finnish Diabetes Risk Score questionnaire adapted to the Colombian population, which enables early diagnosis of the illness, and an algorithm for determining initial treatment that can be generalized to most patients with diabetes mellitus type 2 and that is simple to apply in a primary care context. In addition, several recommendations have been made to scale up pharmacological treatment in those patients that do not achieve the objectives or fail to maintain them during initial treatment. These recommendations also take into account the evolution of weight and the individualization of glycemic control goals for special populations. Finally, recommendations have been made for opportune detection of micro- and macrovascular complications of diabetes.
En Colombia la Diabetes Mellitus es un problema de salud pública por lo que deben generarse e implementarse estrategias de prevención, diagnóstico, tratamiento y seguimiento, aplicables en todos los niveles de atención con miras a establecer el control de la diabetes en forma temprana y sostenida. Se elaboró una guía de práctica clínica siguiendo los lineamientos de la guía metodológica del Ministerio de Salud y Protección Social para recolectar de forma sistemática la evidencia científica y formular las recomendaciones utilizando la metodología GRADE. El presente documento muestra, de forma resumida, el resultado de ese proceso, incluyendo las recomendaciones y las consideraciones tenidas en cuenta para llegar a ellas. En términos generales, se propone un proceso de tamización mediante el cuestionario FINDRISC adaptado a población Colombiana que permite llegar a un diagnóstico temprano de la enfermedad y un algoritmo para el manejo inicial que es generalizable a la gran mayoría de los pacientes con diabetes mellitus tipo 2 y que es sencillo de aplicar en atención primaria. También se hacen unas recomendaciones para escalar el tratamiento farmacológico de los pacientes que no alcanzan la meta o la pierden con el manejo inicial, teniendo en cuenta principalmente la evolución del peso y la individualización de la meta de control glucémico en poblaciones especiales. Finalmente se proponen algunas recomendaciones para la detección oportuna de las complicaciones micro y macrovasculares de la diabetes.
Assuntos
Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/terapia , Adulto , Fatores Etários , Idoso , Albuminúria/diagnóstico , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/diagnóstico , Colômbia , Diabetes Mellitus Tipo 2/prevenção & controle , Dieta para Diabéticos , Quimioterapia Combinada , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemiantes/uso terapêutico , Estilo de Vida , Pessoa de Meia-Idade , Inquéritos e QuestionáriosRESUMO
RESUMEN Introducción: La adherencia al tratamiento es uno de los pilares para lograr el control de cualquier enfermedad, y esto aplica también en la artritis reumatoide. Existen diferentes formas de evaluar el grado de adherencia, siendo las escalas de medición uno de los métodos más usados por su facilidad en aplicación y bajo costo. El objetivo de este estudio fue traducir y validar el Compliance Questionnaire on Rheumatology (CQR) al español y calibrar los puntajes de acuerdo con la actividad de la enfermedad medida mediante DAS-28. Materiales y métodos: En la primera fase del estudio se llevó a cabo el proceso de traducción empleando las guías para la traducción y adaptación cultural de medidas centradas en pacientes. Posteriormente se realizó un proceso de aclaración cognoscitiva. Finalmente se llevó a cabo un estudio de pruebas diagnósticas para determinar el mejor punto de corte para el puntaje de la escala CQR en la identificación del nivel de adherencia al tratamiento antirreumático en pacientes con artritis reumatoide, empleando el DAS 28 como subrogado de adherencia. Resultados: Un total de 233 pacientes con edad promedio de 46,3 (± 13,9) años y tiempo promedio de evolución de enfermedad de 11,2 (±9,6) años. El punto de corte del CQR para establecer adherencia al tratamiento fue de 80,7, con lo cual se obtuvo una sensibilidad del 80,2% (IC 95%: 71,9-86,9%) y una especificidad del 72,3% (IC 95%: 63,1-80,4%). Con este punto de corte se estableció que el 43,8% (n = 102) de los pacientes eran adherentes a la terapia antirreumática oral. Conclusión: Se desarrolló una versión en español del CQR y se calibraron los puntos de corte obteniendo una herramienta práctica y de rápida aplicación clínica, con aceptables sensibilidad y especificidad.
ABSTRACT Introduction: Adherence to treatment is one of the pillars to achieve control of any disease and this also applies to rheumatoid arthritis. There are different ways to assess the level of adherence, and measurement scales are one of the methods most used due to their easy application and low cost. The aim of this study was to translate and validate the Compliance Questionnaire on Rheumatology (CQR) to Spanish and calibrate the scores according to the activity of the disease measured by the DAS-28. Materials and methods: The translation process was carried out in the first phase of the study using guidelines for translation and cultural adaptation of measures focused on patients. This was followed by cognitive clarification process. Finally, a study of diagnostic tests was carried out to determine the best cut-off point for the score on the CQR scale for identifying the level of adherence to rheumatic therapy in patients with rheumatoid arthritis using the DAS-28 as subrogated adherence. Results: The study included 233 patients, with a mean age of 46.3 (±13.9) years and mean time with the disease of 11.2 (±9.6) years. The CQR cut-off to establish adherence to treatment was 80.7. This achieved a sensitivity of 80.2% (95% CI: 71.9-86.9%) and specificity of 72.3% (95% CI: 63.1-80.4%). With this cut-off point, it was established that there was 43.8% (n = 102) patient adherence to oral rheumatic therapy. Conclusion: CQR Spanish version of the CQR was developed and calibrated obtaining a practical tool, with acceptable sensitivity and specificity.
Assuntos
Humanos , Pessoa de Meia-Idade , Artrite Reumatoide , Inquéritos e Questionários , Cooperação e Adesão ao Tratamento , Sensibilidade e Especificidade , Testes Diagnósticos de RotinaRESUMO
ABSTRACT Context: Patients with rheumatoid arthritis have a higher cardiovascular risk due to the prevalence of cardiovascular risk factors and metabolic alterations derived from the inflammatory activity and the treatment of their disease. A systematic evaluation of the effect of statins on lipid fractions and cardiovascular outcomes has not been carried out specifically in patients with rheumatoid arthritis. Methods: A literature search was conducted in Medline (PubMed), Embase, Lilacs, SciELO, and Cochrane. Randomized and non-randomized clinical trials were selected that evaluated the impact of statins on mortality, cardiovascular events, lipid fractions and disease activity in patients with rheumatoid arthritis. A paired evaluation of risk of bias was carried out, along with a meta-analysis using RevMan 5.3®. Results: A total of 5 studies and 383 patients were included in the analysis. The use of statins among patients with rheumatoid arthritis significantly reduced total cholesterol levels: -46.16mg/dL (95% CI: [-53.89, -38.46]; I 2: 86%), LDLc: -18.13mg/dL (95% CI: [-21.8, -14.4], I 2: 97%) and TG of -34.95 mg/dL (95% CI: [-44.3, -25.6], I 2: 0%), without significant changes in HDLc. It also reduced the activity of the disease (DAS28) by 0.73 (95% CI: [-0.94, -0.53], I 2: 96%). No study was found that reported mortality or cardiovascular outcomes. Conclusion: The lipid-lowering effect of statins in patients with rheumatoid arthritis is consistent with that found in other populations. There is a slight impact in reducing the activity of the disease, but reducing the risk of cardiovascular events in this specific population has not been studied.
RESUMEN Contexto: Los pacientes con artritis reumatoide tienen un riesgo cardiovascular elevado por la alta prevalencia de factores de riesgo cardiovascular y de alteraciones metabólicas derivadas de la actividad inflamatoria y del tratamiento de su enfermedad. No se ha realizado una evaluación sistemática del efecto de las estatinas en las fracciones lipídicas y desenlaces cardiovasculares específicamente en pacientes con artritis reumatoide. Métodos: Se realizó una búsqueda de la literatura en Medline (PubMed), Embase, Lilacs, SciELO y Cochrane. Se seleccionaron experimentos clínicos aleatorizados y no aleatorizados (estudios de cohortes) que evaluaran el impacto de las estatinas en mortalidad, eventos cardiovasculares, fracciones lipídicas y actividad de la enfermedad en pacientes con artritis reumatoide. Se realizó la selección, evaluación del riesgo de sesgos de forma pareada y un metaanálisis con RevMan 5.3®. Resultados: Un total de 5 estudios y 383 pacientes fueron incluidos en el análisis. El uso de estatinas en pacientes con artritis reumatoide reduce significativamente los niveles de colesterol total: -46,16 mg/dL (IC 95%: [-53,89; -38,46]; I 2: 86%), LDLc: -18,13 mg/dL (IC 95%: [-21,8; -14,4]; I 2: 97%) y triglicéridos de -34,95 mg/dL (IC 95%: [-44,3; -25,6]; I 2: 0%), sin cambios significativos del HDLc. Además, reduce la actividad de la enfermedad (DAS28) en 0,73 (IC 95%: [-0,94; -0,53]; I 2: 96%). No se encontró ningún estudio que reportara mortalidad ni desenlaces cardiovasculares. Conclusión: El efecto hipolipidemiante de las estatinas en pacientes con artritis reumatoide es consistente con lo encontrado en otras poblaciones. Existe un discreto impacto en la reducción de actividad de la enfermedad; sin embargo, la reducción del riesgo de eventos cardiovasculares en esta población específica no ha sido estudiada.
Assuntos
Humanos , Artrite Reumatoide , Inibidores de Hidroximetilglutaril-CoA Redutases , Triglicerídeos , Fatores de Risco , Comportamento de Redução do RiscoRESUMO
Antisynthetase antibody syndrome is a rare autoimmune disease that may present with variable systemic manifestations, mainly polymyositis, interstitial lung disease, skin lesions, and Raynaud's phenomenon. This diagnosis should always come to mind in patients that present with signs of myositis, dermatomyositis, or polymyositis associated with interstitial lung disease. On the following paper, we report the case of a 52-year-old man who presented with a 2-month history of asymmetric polyarthralgia, myalgia, weight loss of 8 kg, and progressive muscle weakness associated with dyspnea, orthopnea, and dysphonia. Further tests revealed myositis, interstitial pneumonia, and elevation of anti-Jo-1 antibodies. A diagnosis of antisynthetase antibody syndrome was made and the patient showed good response to treatment with corticoids and methotrexate. Finally, we present a short review of the literature.
Assuntos
Doenças Pulmonares Intersticiais/diagnóstico , Miosite/diagnóstico , Anticorpos Antinucleares/imunologia , Artralgia/diagnóstico , Biópsia , Humanos , Doenças Pulmonares Intersticiais/complicações , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/diagnóstico , Músculos/patologia , Mialgia/diagnóstico , Miosite/complicações , Miosite/terapia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Redução de PesoRESUMO
Abstract C1q nephropathy was first described in 1985 as a process of glomerulonephritis with mesangial C1q deposit. The histology is similar to lupus nephritis, and was initially described as being seronegative renal lupus. However, these two entities are now considered different pathological processes. Its association with rheumatoid arthritis is unusual, and there are no cases with a similar presentation reported in the literature. In this article, the case is presented of a man who developed both these conditions.
Resumen La nefropatía C1q, se describió por primera vez en 1985, como un proceso de glomerulonefritis con depósito mesangial de C1q, histológicamente similar a la nefritis lúpica, siendo inicialmente descrita como lupus renal seronegativo, sin embargo, estas dos entidades se consideran actualmente como procesos patológicos diferentes. Su asociación con artritis reumatoide es inusual y la literatura no reporta casos con presentación similar. A continuación, presentamos el caso de un hombre que desarrolla estas dos entidades.
Assuntos
Humanos , Masculino , Adulto , Artrite Reumatoide , Nefropatias , Processos Patológicos , Associação , Células Mesangiais , Glomerulonefrite , HistologiaRESUMO
Resumen Introducción: Los instrumentos de tamizaje de artritis psoriásica son una herramienta útil en la consulta dermatológica, para optimizar la remisión al reumatólogo. La herramienta Toronto Psoriatic Arthritis Screening Questionnaire (ToPAS) ha sido desarrollada y validada en Canadá. Objetivos: Traducir y aplicar algunas pruebas de validación de la escala ToPAS para ser utilizada en la consulta dermatológica en Colombia. Métodos: Estudio de traducción y validación de escalas. Resultados: Se llevó a cabo la traducción y validación del ToPAS con una metodología estandarizada, obteniendo un documento en español con el cual se realizó una prueba piloto del documento final en 20 pacientes con diagnóstico de psoriasis y artritis psoriásica, con el fin de evaluar los ítems en cuanto a aspectos como comprensión, ambigüedad y tiempo de respuesta. Posteriormente, el instrumento se aplicó a 108 pacientes, 65 (60,2%) eran hombres, 36 (33,3%) tenían diagnóstico de artritis psoriásica y 72 (66,6%) solo psoriasis. Se consideró como punto de corte un puntaje > 8 puntos, encontrando una sensibilidad del 75% y una especificidad del 92%, valor predictivo positivo del 82% y valor predictivo negativo del 88%. Para evaluar la confiabilidad test-retest se seleccionaron los últimos 25 participantes, calculándose el coeficiente de correlación de Pearson para evaluar la correlación entre la primera y la segunda aplicación del ToPAS; el valor de p fue de 0,94, valor que representa un alto nivel de correlación entre la primera y la segunda aplicación. Conclusiones: Se realizó la traducción, validación y evaluación de características operativas de la encuesta ToPAS para detección de artritis psoriásica, constituyéndose en una herramienta práctica para uso en la consulta dermatológica.
Abstract Introduction: Psoriatic arthritis screening tools are useful for the rheumatologist in optimising referrals to the dermatology clinic. The Toronto Psoriatic Arthritis Screening Questionnaire (ToPAS) is a tool that has been developed and validated in Canada. Objectives: To translate, and perform some validation tests on TOPAS for use in dermatology clinics in Colombia. Methods: Translation and validation of scales. Results: ToPAS was translated using standardised methodology. A pilot test was conducted on 20 patients diagnosed with psoriasis and psoriatic arthritis using the final version of the document translated into Spanish, in order to evaluate items of aspects such as understanding, ambiguity, and response time. The tool was then used on 108 patients, including 65 (60.2%) males, with 36 (33.3%) cases with a diagnosis of psoriatic arthritis, and 72 (64.7%) with psoriasis only. Using a cut-off score > 8 points, it showed a sensitivity of 75% and specificity 92%, positive predictive value 82% and negative predictive value of 88%. To assess the reliability test re-test, 25 participants were selected and Pearson correlation coefficient was calculated to evaluate the correlation between the first and second application of ToPAS, which gave a value of P = .94, which represents a high level of correlation between the first and second application. Conclusions: A translation, validation and evaluation of operational characteristics of the ToPAS questionnaire was conducted, being a practical tool for use in the dermatology clinic.
Assuntos
Humanos , Artrite Psoriásica , Inquéritos e Questionários , Encaminhamento e Consulta , Dermatopatias , Canadá , Programas de Rastreamento , DiagnósticoRESUMO
Introducción: Existen diferentes opciones de manejo para pacientes con diabetes mellitus tipo 2 (DMT2) que ya iniciaron tratamiento farmacológico con metformina y no han alcanzado metas de control glucémico. Resulta prioritario definir pautas para escoger la mejor opción en estos pacientes, así como en aquellos que no han tenido un control óptimo con la combinación de dos medicamentos. Objetivo: Definir cuál es antidiabético de elección, entre sulfonilureas, tiazolidinedionas, inhibidores de DPP-4, agonista del receptor de GLP-1 o insulina basal, como segunda y tercera líneas de manejo en pacientes con DMT2. Métodos: Se elaboró la guía de práctica clínica, siguiendo los lineamientos de la guía metodológica del Ministerio de Salud y Protección Social colombiano. Se revisó la evidencia disponible de forma sistemática y se formularon las recomendaciones utilizando la metodología GRADE. Conclusiones: En pacientes con DMT2 y falla terapéutica al manejo con metformina como monoterapia (HbA1C > 7 %) se recomienda como primera opción adicionar un inhibidor DPP-4, como segunda opción adicionar inhibidor SGLT2 o sulfonilureas con bajo riesgo de hipoglucemia y como tercera opción agregar insulina basal a los pacientes que con la combinación de dos fármacos fallen en alcanzar su meta de HbA1C. Si la falla terapéutica se asocia con un IMC persistentemente ≥ 30, se sugiere la adición de un agonista de GLP-1 por el potencial beneficio sobre la reducción de peso.
Introduction: There are different options to treat type 2 diabetes (DMT2) patients who began treatment with metformin and have not reached therapeutic golds. It is imperative to define rules to choose the best option, in these patients, as in those who have not achieved an optimal control under combined therapy. Aim: To define the best option between sulfonylureas, thiazolidinediones, DPP4 inhibitors, GLP-1 agonist or basal insulin, as second or third line treatment, in patients with DMT2 who have not reached therapeutic golds with metformin or combined therapy. Methods: A clinical practice guide has been developed following the broad outline of the methodological guide from the Colombian Ministry of Health and Social Welfare, with the aim of systematically gathering scientific evidence and formulating recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. Conclusions: In patients with DMT2 who did not reach their therapeutic goal with metformin as a monotherapy (Hb1Ac <7%), addition of a second oral antidiabetic medication is recommended. it is recommended as a first step to add a DPP-4 inhibitor. It is suggested to add a SGLT2 inhibitor or a sulfonylurea having low risk of hypoglycemia as acceptable options. It is suggested to add basal insulin as a third antidiabetic medication if the combination of two pharmacological treatments does not enable the patient to reach and maintain the HbA1c goal. It is suggested to add a GLP-1 agonist if therapeutic failure appears in patients who remain obese (BMI ≥30 kg/m²), considering its potential to reduce weight.
Assuntos
Humanos , Diabetes Mellitus Tipo 2 , Falha de Tratamento , MetforminaRESUMO
La serositis es uno de los hallazgos clínicos en pacientes con lupus eritematoso sistémico.Cuando se presenta a nivel de pericardio, generalmente causa derrames pericárdicos cró-nicos que no generan inestabilidad hemodinámica en el paciente. Presentamos 2 casosclínicos de mujeres con lupus con derrame pericárdico que lleva a taponamiento cardiaco,presentación inusual de esta manifestación clínica del lupus eritematoso sistémico...
Serositis is one of the clinical findings in patients with systemic lupus erythematosus. Whenis present generally causes chronic pericardial effusions and not generate hemodynamicinstability in the patient. We present two cases of women with lupus with pericardial effusionleading to cardiac tamponade, unusual presentation of this clinical manifestation insystemic lupus erythematosus...
Assuntos
Humanos , Tamponamento Cardíaco , SerositeAssuntos
Anti-Inflamatórios/efeitos adversos , Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Meningite Criptocócica/induzido quimicamente , Meningoencefalite/induzido quimicamente , Meningoencefalite/microbiologia , Metotrexato/efeitos adversos , Prednisona/efeitos adversos , Anti-Inflamatórios/uso terapêutico , Antirreumáticos/uso terapêutico , Feminino , Humanos , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Prednisona/uso terapêuticoRESUMO
We report the case of a 70-year-old male with chronic abdominal pain, who presented with increased intensity of the pain, and was initially diagnosed and treated for acute biliary pancreatitis. However, the symptoms persisted after hospital discharge, and he was subsequently studied with cholangio-MRI, abdominal CT scan, and ERCP, which revealed dilation of the biliary tract and a mass in the head of the pancreas. An excisional biopsy of the lesion showed chronic inflammation with severe sclerosing fibrosis and a lymphoplasmacytic infiltrate. A diagnosis of autoimmune pancreatitis was made, and the patient was initiated on azathioprine with good clinical response.
Presentamos el caso de un varón de 70 años con dolor abdominal crónico, que se presenta con aumento de este; se le diagnostica y se lo trata inicialmente como cuadro de pancreatitis biliar. A pesar del manejo inicial, los síntomas persisten después de la primera hospitalización, y se estudia con tomografía computarizada de abdomen, colangiorresonancia y colangiopancreatografía retrograda endoscópica, estudios en los cuales se detecta dilatación de la vía biliar y masa en la cabeza del páncreas. Se llevó a cabo biopsia excisional, que demuestra inflamación crónica con intensa fibrosis e infiltrado linfocitario. Se hace diagnóstico de pancreatitis autoimmunitaria y se inicia azatioprina, con adecuada respuesta.
Assuntos
Humanos , Dor Abdominal , ColelitíaseRESUMO
El síndrome de Felty es la tríada de artritis, esplenomegalia y neutropenia. Adicionalmente, sepueden encontrar en este síndrome múltiples factores propios de la artritis reumatoide, entreellos la presencia de nódulos pulmonares. Presentamos el caso de un paciente con hallazgosclínicos y paraclínicos que evidencian la presencia del síndrome de Felty, presentando, además,nódulos pulmonares en los estudios radiológicos e histológicos que documentaron granulomascrónicos, bronquiolitis obliterante y neumonía organizante.